Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 22;10(3):416.
doi: 10.3390/jcm10030416.

The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review

Giorgio Ivan Russo  1 , Gaetano Larganà  1 , Arcangelo Sebastianelli  2 , Andrea Cocci  2 , Marina Di Mauro  1 , Ilenia Rapallo  1 , Giuseppe Morgia  1 , Matteo Mario Morgia  1 , Sandro La Vignera  3 , Rosita Condorelli  3 , Aldo E Calogero  3 , Iacopo Olivotto  4 , Simone Morselli  2 , Sergio Serni  2 , Mauro Gacci  2
Affiliations
Review

The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review

Giorgio Ivan Russo et al. J Clin Med. .

Abstract

Previous data have shown that patients with metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) could be refractory to the medical treatment. In this context, the evidence suggests a role for statin use in LUTS/BPE patients. The present systematic review aimed to evaluate the impact of statins on the treatment of men with LUTS/BPE. This review has been registered on PROSPERO (CRD42019120729). A systematic review of English-language literature was performed up to January 2020 in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA statement) criteria. Retrieved studies had to include adults with LUTS connected to BPE treated with statins drugs for metabolic syndrome. After removing duplicates, a total of 381 studies were identified by the literature search and independently screened. Of these articles, 10 fit the inclusion criteria and were further assessed for eligibility. Data from our systematic review suggest that a long-term therapy with statins, at least 6 months, is required to achieve significant impacts on prostate tissue and LUTS. Moreover, besides statins' direct activity, the risk reduction of LUTS might be connected to the improvement of hypercholesterolemia and MetS. The role of statins for the treatment of LUTS/BPE may be beneficial; however, evidence from robust studies is not enough, and more clinical trial are required.

Keywords: LUTS; hypercholesterolemia; metabolic syndrome; prostate; prostate enlargement; tryglycerides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Insights representation of the activity of Ras pathways. Green and purple circles represent the mediator.
Figure 2
Figure 2
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2009 flow diagram.
Figure 3
Figure 3
(A) Risk of bias assessment in randomized studies and (B) summary of randomized studies: review authors’ judgements about each risk of bias item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red = high risk of bias.
Figure 4
Figure 4
Risk of bias assessment in nonrandomized studies according to ROBINS-I tool. ROBINS-I = risk of bias in nonrandomized studies of interventions.
See this image and copyright information in PMC

References

    1. Gratzke C., Bachmann A., Descazeaud A., Drake M.J., Madersbacher S., Mamoulakis C., Oelke P.D.M.M., Tikkinen K.A., Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur. Urol. 2015;67:1099–1109. doi: 10.1016/j.eururo.2014.12.038. - DOI - PubMed
    1. Kupelian V., Wei J.T., O’Leary M.P., Kusek J.W., Litman H.J., Link C.L., McKinlay J.B. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: The Boston Area Community Health (BACH) survey. Arch. Intern. Med. 2006;166:2381–2387. doi: 10.1001/archinte.166.21.2381. - DOI - PubMed
    1. Agarwal A., Eryuzlu L.N., Cartwright R., Thorlund K., Tammela T.L., Guyatt G.H., Auvinen A., Tikkinen K.A.O. What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. Eur. Urol. 2014;65:1211–1217. doi: 10.1016/j.eururo.2014.01.019. - DOI - PMC - PubMed
    1. Wei J.T., Calhoun E., Jacobsen S.J. Urologic diseases in america project: Benign prostatic hyperplasia. J. Urol. 2005;173:1256–1261. doi: 10.1097/01.ju.0000155709.37840.fe. - DOI - PubMed
    1. Pashootan P., Ploussard G., Cocaul A., De Gouvello A., Desgranchamps F. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): An observational study in a 4666 European men cohort. BJU Int. 2014;116:124–130. doi: 10.1111/bju.12931. - DOI - PubMed

LinkOut - more resources